Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 11Sarcoma 6Neoplasms 6Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Kidney Neoplasms 4Gliosarcoma 4Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Waldenstrom Macroglobulinemia 3Osteosarcoma 3Melanoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Endometrial Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Liposarcoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

Gemcitabine 5Paclitaxel 4Nivolumab 3cobimetinib 2atezolizumab 2adavosertib 2Ramucirumab 2N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 2Carboplatin 2zansecimab 1tocilizumab 1tivozanib 1tislelizumab 1temsirolimus 1ridaforolimus 1plocabulin 1pexidartinib 1pevonedistat 1pembrolizumab 1pamiparib 1obinutuzumab 1necitumumab 1liposomal doxorubicin 1lenvatinib 1glasdegib 1futuximab 1demplatin pegraglumer 1birinapant 1avelumab 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solid Tumors × temsirolimus × Clear all
NCT01369433 2020-09-01

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

AVEO Pharmaceuticals, Inc.

Phase NA Terminated
225 enrolled 7 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡